Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
AR-12286 0.5% Ophthalmic Solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Conditions
Glaucoma, Open-angle, Ocular Hypertension
Interventions
Combination IOP Lowering Therapy
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Open Angle Glaucoma
Interventions
CycloPen Cyclodialysis System
Device
Lead sponsor
Iantrek, Inc.
Industry
Eligibility
21 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
15
States / cities
Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more
Conditions
Open-Angle Glaucoma
Interventions
Blood Collection Only
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Completed Phase 2 Interventional Results available

SYL040012, Treatment for Open Angle Glaucoma

NCT02250612
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran), 1 drop of 1.5% SYL040012 (bamosiran), 1 drop of 0.5 % timolol maleate
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Artesia, California • Petaluma, California • Morrow, Georgia + 1 more
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 6 more
Conditions
Glaucoma
Interventions
EYETRONIC Nextwave System
Device
Lead sponsor
Glaucoma Center of San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
brinzolamide 1.0%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Conditions
Open-angle Glaucoma, Oular Hypertension
Interventions
Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL, Anecortave Acetate Vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Glaucoma
Interventions
OrCam
Device
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution
Combination Product · Drug
Lead sponsor
PolyActiva Pty Ltd
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Conditions
Glaucoma, Ocular Hypertension
Interventions
Not listed
Lead sponsor
Robin, Alan L., M.D.
Individual
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Ocular Hypertension
Interventions
bimatoprost/timolol fixed combination
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Ogden, Utah
Conditions
Glaucoma, Primary Open Angle, Cataract
Interventions
Intracanalicular Dexamethasone, 0.4 mg insert
Drug
Lead sponsor
Wolstan and Goldberg Eye Associates
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Torrance, California
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Glaucoma therapy
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Multiple Locations Throughout the US Sponsored by Alcon of, Texas
Conditions
Glaucoma
Interventions
Music intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
8 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Not listed Not applicable Interventional Accepts healthy volunteers

CLAD Deconvolved PERG Responses in Glaucoma Patients

NCT06388096
Conditions
Glaucoma, Suspect
Interventions
Pattern Electroretinogram
Diagnostic Test
Lead sponsor
Jorvec Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
20 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Francisco, California
Conditions
Glaucoma
Interventions
Eye Drop Aid
Device
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Up to 99 Years
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Conditions
Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
iStent infinite trabecular micro-bypass system model iS3, iDose TR (Travoprost intracameral Implant) 75mcg
Device · Drug
Lead sponsor
Jonathon Myers
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 1Phase 2 Interventional Results available

Macular Pigment and Visual Performance in Glaucoma Patients

NCT03959592
Conditions
Glaucoma
Interventions
Lutein, zeaxanthin and mesozeaxanthin, Placebo
Drug · Other
Lead sponsor
Felipe Medeiros, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Glaucoma, Cataract, Presbyopia
Interventions
Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL
Procedure
Lead sponsor
Vance Thompson Vision
Other
Eligibility
45 Years and older
Enrollment
27 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Conditions
Glaucoma, Dry Eye Syndrome, Conjunctivitis
Interventions
Not listed
Lead sponsor
Robin, Alan L., M.D.
Individual
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland